Modulation of CD4 T cell function by soluble MHC II-peptide chimeras

References

• Sykulev Y., Cohen R. J., Eisen H. N. The law of mass action governs antigen-stimulated cytolytic activity of CD8 cytotoxic T lymphocytes. P.N.A.S. USA 1995; 92: 11990–11992
   PubMed Web of Science ®Google Scholar
• Schodin B. A., Tsomides T. J., Kranz D. M. Correlation between the number of T cell receptors required for T cell activation and TCR-ligand affinity. Immunity 1996; 5: 137–146
   PubMed Web of Science ®Google Scholar
• Liu C-P., Crawford F., Marrack P., Kappler J. T cell positive selection by a high density, low affinity ligand. P.N.A.S. USA 1998; 95: 4522–4526
   PubMed Web of Science ®Google Scholar
• Ashton-Rickardt P. G., Bandeira A., Delaney J. R., Van Kaer L., Pircher H-P., Zinkernagel R. M., Tonegawa S. Evidence for a different avidity model of T cell selection in the thymus. Cell 1994; 76: 651–663
   PubMed Web of Science ®Google Scholar
• De Magistris M. T., Alexander J., Coggeshall M., Altman A., Gaeta F. C., Grey H. M., Sette A. Antigen-analog histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992; 68: 625–634
   PubMed Web of Science ®Google Scholar
• Soloway P., Fish S., Passmore H., Gefter M., Coffee R., Manser T. Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype. J. Exp. Med. 1991; 174: 847–858
   PubMedGoogle Scholar
• Racioppi L., Ronchese F., Matis L. A., Germain R. N. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J. Exp. Med. 1993; 177: 1047–1060
   PubMed Web of Science ®Google Scholar
• Hansburg D., Fairwell T., Schwartz R. H., Appella E. The T lymphocyte response to cytochrome c. IV. Distinguishable sites on a peptide antigen which affect antigenic strength and memory. J. Immunol. 1983; 131: 319–324
   PubMed Web of Science ®Google Scholar
• Windhagen A., Scholz C., Hollsberg P., Sette A., Hafler D. A. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995; 2: 373–382
   PubMed Web of Science ®Google Scholar
• Kersh G. J., Kersh E. N., Fremont D. H., Allen P. M. High-and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 1998; 9: 817–826
   PubMed Web of Science ®Google Scholar
• Germain R. N., Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 1999; 17: 467–522
   PubMed Web of Science ®Google Scholar
• McKeithan T. W. Kinetics proofreading in T cell receptor signal transduction. P.N.A.S. USA 1995; 92: 5042–5046
   PubMed Web of Science ®Google Scholar
• Rabinowitz J. D., Beeson C., Lyons D. S., Davis M. M., McConnell H. M. Kinetic discrimination in T cell activation. P.N.A.S. USA 1996; 93: 1401–1405
   PubMed Web of Science ®Google Scholar
• Lyons D. S., Lieberman S. A., Hampl J., Boniface J. J., Chien Y-h., Ber L. J., Davis M. M. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates tan agonists. Immunity 1996; 5: 53–61
   PubMed Web of Science ®Google Scholar
• Davis M. M., Boniface J. J., Reich Z., Lyons D., Hampl J., Arden B., Chien Y-H. Ligand recognition by T cell receptors. Annu. Rev. Immunol. 1998; 16: 523–544
   PubMed Web of Science ®Google Scholar
• Reich Z., Boniface J. J., Lyons D. S., Borochov N., Wachte E. J., Davis M. M. Ligand-specific oligomerization of T cell receptor molecules. Nature 1997; 387: 617–620
   PubMed Web of Science ®Google Scholar
• Brown J. H., Jardetzky T. X., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33–39
   PubMed Web of Science ®Google Scholar
• Grakoui A., Bromley S. K., Sumen C., Davis M. M., Shaw A. S., Allen P. M., Dustin M L. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285: 221–227
   PubMed Web of Science ®Google Scholar
• Porgador A., Yewdell J. W., Deng Y., Bennink J. R., Germain R. N. Localization, quantitation and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6: 715–726
   PubMed Web of Science ®Google Scholar
• Dadaglio G., Nelson C. A., Deck M. B., Petzold S. J., Unanue E. R. Characterization and quantification of peptide-MHC complexes produced from egg lysozyme using a monoclonal antibody. Immunity 1997; 6: 727–738
   PubMed Web of Science ®Google Scholar
• Andersen P. S., Stryhn A., Hansen B. E., Fugger L., Engberg J., Buus S. A. Recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. P.N.A.S. USA 1996; 93: 1820–1824
   PubMed Web of Science ®Google Scholar
• Corr M., Slanetz A. E., Boyd L. F., Jelonek M. T., Khilko S., al-Ramadi B. K., Kim Y. S., Maher A. E., Bothwell A. L., Margulies D. H. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 1994; 265: 946–949
   PubMed Web of Science ®Google Scholar
• Matsui K., Boniface J. J., Steffner P., Reay P. A., Davis M. M. Kinetics of T cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T cell responsiveness. P.N.A.S. USA 1994; 91: 12862–12866
   PubMed Web of Science ®Google Scholar
• Seth A., Stern L. J., Ottenhoff T. H., Engel I., Owen M. J., Lamb J. R., Klausner R. D., Wiley D. C. Binary and ternary complexes between T cell receptor, class II MHC and superantigen in vitro. Nature 1994; 369: 324–327
   PubMed Web of Science ®Google Scholar
• al-Ramadi B. K., Jelonek M. T., Boyd L. F., Margulies D.h., Bothwell A. L. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J. Immunol. 1995; 155: 662–673
   PubMed Web of Science ®Google Scholar
• Garcia K. C., Scott C. A., Brunmark A., Carbone F. R., Peterson P. A., Wilson I. A., Teyton L. CD28 enhances formation of stable T cell receptor/MHC class I molecule complexes. Nature 1996; 384: 577–581
   PubMed Web of Science ®Google Scholar
• Alam S. M., Travers P. J., Wung J. L., Nasholds W., Redpath S., Jameson S. C., Gascoiggne N. R. T cell receptor affinity and thymocyte positive selection. Nature 1996; 381: 616–620
   PubMed Web of Science ®Google Scholar
• Seibel J. L., Wilson N., Kozono H., Marrack P., Kappler J. W. Influence of the NH2-terminal amino acid of the T cell receptor alpha chain on major histocompatibility complex (MHC) class II+ peptide recognition. J. Exp Med. 1997; 185: 1919–1927
   PubMed Web of Science ®Google Scholar
• Matsui K., Boniface J. J., Reay P. A., Schild H., Fazekas de St. Groth B., Davis M. M. Low affinity interaction of peptide-MC complexes with T cell receptor. Science 1991; 254: 1788–1791
   PubMed Web of Science ®Google Scholar
• Weber S., Traunecker A., Oliveri S., Gerhard W., Karjalainen K. Specific low-affinity recognition of major histocompatibility complexes plus peptide by soluble T cell receptor. Nature 1992; 356: 793–796
   PubMed Web of Science ®Google Scholar
• Sykulev Y., Brunmark A., Jackson M., Cohen R. J., Peterson P. A., Eisen H. N. Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity 1994; 1: 15–22
   PubMed Web of Science ®Google Scholar
• Sykulev Y., Brunmark A., Tsmds T. J., Kagyama S., Jackson M., Hansen H. N. High-affinity reactions between antigen-specific T cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. P.N.A.S. USA 1994; 91: 11487–11491
   PubMed Web of Science ®Google Scholar
• Luescher I. F., Vivier E., Layer A., Mahiou J., Godeau F., Malissen B., Romero P. CD8 modulation of T cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature 1995; 373: 353–356
   PubMed Web of Science ®Google Scholar
• Kessler B. M., Bassanini P., Cerottini J. C., Luescher I. F. Effect of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. J. Exp. Med. 1997; 185: 629–640
   PubMed Web of Science ®Google Scholar
• Sant'Angelo D. B., Waterbury G., Preston-Hurlburt P., Yoon S. T., Medzihov R., Hong S. C., Janeway C. A., Jr. The specificity and orientation of a TCR to its peptide-MC class II ligands. Immunity 1996; 4: 367–376
   PubMed Web of Science ®Google Scholar
• Jorgenssen J. L., Reay P. A., Hussey R. E., Hodgdon J. C., Schlossman S. F., Reinherz E. L. Relationship to the T3 molecular complex. J. Exp. Med. 1983; 157: 705–719
   PubMed Web of Science ®Google Scholar
• Fields B. A., Malchioli E. L., Li H., Ysern X., Stauffacher C. V., Schlievert P. M., Karjalainen K., Mariuzza R. A. Crystal structure of a T cell receptor beta-chain complexed with superantigen. Nature 1996; 384: 188–192
   PubMed Web of Science ®Google Scholar
• Jardetzky T. S., Brown J. H., Gorga J. C., Stern L. J., Urban R. G., Chi Y. I., Stauffacker C., Strominger J., Wiley D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994; 368: 711–718
   PubMed Web of Science ®Google Scholar
• Li H., Llera A., Tsuchira D., Leder L., Ysern X., Schlivert P. M., Karjalainen K., Maruizza R. A. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 1998; 9: 807–816
   PubMed Web of Science ®Google Scholar
• Reinherz E. L., Tan K., Tang L., Kern P., Liu J-h., Xiong Y., Hussey R. E., Smolyar A., Hare B., Zhang R., Joachimiak A., Chang H.-C., Wagner G., Wang J.-H. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 1999; 286: 1913–1921
   PubMed Web of Science ®Google Scholar
• Smith K. J., Pyrdol J., Gauthier L., Wiley D. C., Wucherpfennig K. W. Crystal structure of HLA-DR2 (DRA* 0101, DRB1* 1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 1998; 188: 1511–1520
   PubMed Web of Science ®Google Scholar
• Wucherpfennig K. W., Strominger J. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695–705
   PubMed Web of Science ®Google Scholar
• Clayton L. K., Sieh M., Pious D. A., Reinherz E. L. Identification of human CD4 residues affecting class II MHC versus HIV-I gpl20 binding. Nature 1989; 339: 548–551
   PubMed Web of Science ®Google Scholar
• Moebius U., Clayton L. K., Abraham S., Diener A., Yunis J. J., Harrison S. C., Reinherz E. L. Human immunodeficiency virus gp 120 binding C'C” ridge of CD4 domain I is also involved in interaction with class II major histocompatibility complex molecules. P.N.A.S. USA 1992; 87: 12008–12012
   Web of Science ®Google Scholar
• Moebius U., Pallai P., Harrison S. C., Reinherz E. L., E. L. Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding. P.N.A.S. USA 1993; 90: 8259–8263
   PubMed Web of Science ®Google Scholar
• Houlgatte R., Scarmato P., Mahormy E. S., Martin M., Ostankovitch M., Lafosse S., Vervisch A., Auffray C., Platier-Tonneau D. HLA class II antigens and the HIV envelope glycoprotein gpl20 bind to the same face of CD4. J. Immunol. 1994; 152: 4475–4488
   PubMed Web of Science ®Google Scholar
• Konig R., Huan L.-Y., Germain R. N. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 1992; 356: 796–798
   PubMed Web of Science ®Google Scholar
• Hussey R. E., Richardson N. E., Kowalsk I. M., Brown N. R., Chang H. C., Siliciano R. F., Dorfman T., Walker B., Sodroski J., Reinherz E. L. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331: 78–81
   PubMed Web of Science ®Google Scholar
• Wang J. H., Yan Y. W., Garrett T. P., Rodger D. W., Garlick R. L., Tarr G. E., Husain Y., Reinherz E. L., Harrison S. C. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature 1990; 348: 411–418
   PubMed Web of Science ®Google Scholar
• Ryu S.-E., Kwong P. D., Truneh A., Porter T. G., Arthos G., Rosenberg M., Dai X. P., Xuong N. H., Axel R., Sweet R. W. Molecular characteristics of an HIV-binding recombinant fragment of human CD4. Nature 1990; 348: 419–426
   PubMed Web of Science ®Google Scholar
• Kwong P. D., Ryu S.-E., Hendrickson W. A., Axel R., Sweet R. M., Folena-Wasserman G., Hensley P., Sweet R. W. Molecular characteristics of recombinant human CD4 as deduced from polymorphic crystals. P.N.A.S. USA 1990; 87: 6423–6427
   PubMed Web of Science ®Google Scholar
• Brown J. H., Jardetzky T. S., Gorga J. C., Stern J. L., Urban R. G., Strominger J., Wiley D. C. Three-dimensional structure of the human class II major histocompatibility antigen HLA-DR1. Nature 1993; 364: 33–39
   PubMed Web of Science ®Google Scholar
• Mazerolles F., Amblard F., Lumbroso C., Lecompte O., van der Moortele P. F., Barbat C., Piatier-Tonneau D., Auffray C., Fischer A. Regulation of T helper-Blymphocyte adhesion through CD4-HLA class II interaction. Eur. J. Immunol. 1990; 20: 637–644
   PubMed Web of Science ®Google Scholar
• Nag B., Wada H. G., Passmore D., Clark B. R., Sharma S. D., MsCornell H. M. Purified β-chain of MHC class II binds to CD4 molecules on transfected HeLa cells. J. Immunol. 1993; 150: 1358–1364
   PubMed Web of Science ®Google Scholar
• Sakihama T., Smolyar A., Reinherz E. L. Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Immunol. Today 1995; 16: 581–587
   PubMedGoogle Scholar
• Konig R., Fleury S., Germain R. N. The structural basis of CD4-MHC class II onteractions: coreceptor contributions to T cell receptor antigen recognition and oligomerization-dependent signal transduction. Curr. Topics Microbiol. Immunol. 1996; 205: 19–46
   PubMed Web of Science ®Google Scholar
• Monks C. R., Freiberg B. A., Kupfer H., Sciaky N., Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998; 395: 82–86
   PubMed Web of Science ®Google Scholar
• Krummel M. F., Sjaastad M. D., Wulfing C., Davis M. M. Differential clustering of CD4 and CD3 zeta during T cell recognition. Science 2000; 289: 1349–1352
   PubMed Web of Science ®Google Scholar
• Kozono H., Whit J., Clements J., Marrack P., Kappler J. W. Production of soluble MHC class II proteins with covalently bound peptides. Nature 1994; 369: 151–154
   PubMed Web of Science ®Google Scholar
• Casares S., Bona C. A., Brumeanu T.-D. Engineering and characterization of a murine MHC class II-Immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Engineering 1997; 10: 1295–1301
   PubMedGoogle Scholar
• Hamad A. R.A., O'Herrin S., Lebowitz M. S., Srikishann A., Bieler J., Schneck J., Pardoll D. Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. J. Exp. Med. 1998; 188: 1633–1640
   PubMed Web of Science ®Google Scholar
• Appel H., Gauthier L., Pyrdol J., Wucherpfennig K. W. Kinetics of T cell receptor binding by bivalent HLA-DR/peptide complexes that activate antigen-specific human T cells. J. Biol. Chem. 2000; 275: 312–32
   PubMed Web of Science ®Google Scholar
• Crawford F., Kozono H., White J., Marrack P., Kappler J. W. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998; 8: 675–682
   PubMed Web of Science ®Google Scholar
• Cochran J. R., Cameron T. O., Stern J. L. The relationship of MHC-peptide binding and T cell activation probed with chemically defined MHC class II oligomers. Immunity 2000; 12: 241–250
   PubMed Web of Science ®Google Scholar
• Casares S., Bona C., Brumeanu T.-D. Enzymatically mediated engineering of multivalent MHC II-peptide chimeras. Protein Engineering 2001; 14, (in press)
   PubMedGoogle Scholar
• Boniface J. J., Rabinowitz R. D., Wulfing C., Hampl J., Reich Z., Altman J. D., Kantor R., Beeson C., McCornell H. M., Davis M. M. Initiation of signal transduction through the T cell receptor requires multivalent engagement of peptide/MHC ligands. Immunity 1998; 9: 459–466
   PubMed Web of Science ®Google Scholar
• Cochran J. R., Stern J. L. A diverse set of oligomeric class II MHC-peptide complexes for probing T cell receptor interactions. Chem. Biol. 2000; 7: 683–696
   PubMedGoogle Scholar
• Casares S., Zong C. S., Radu D. L., Miller A., Bona C. A., Brumeanu T.-D. Antigen-specific signaling by a soluble, dimeric peptide/MHC Class II/Fc chimera leading to Th2 differentiation. J. Exp. Med. 1999; 190: 543–553
   PubMed Web of Science ®Google Scholar
• Brumeanu T.-D., Bona C. A., Casares S. T cell tolerance and autoimmune diabetes. Intl. Immunol. 2001, (in press)
   Web of Science ®Google Scholar
• Combadiere B., e Sousa C. R., Germain R. N., Lenardo M. J. Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands. J. Exp. Med. 1998; 187: 349–355
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Understanding the mechanisms of sustained signaling and T cell activation. J. Exp. Med. 1997; 185: 1717–1719
   PubMed Web of Science ®Google Scholar
• Casares S., Bona C., Brumeanu T.-D. Antigen-specific down-regulation of T cells by doxorubicin delivered by MHC II-peptide chimeras. Nature Biotechnology 2001; 19: 142–147
   PubMed Web of Science ®Google Scholar
• Mosmann T. R., Coffman R. L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1998; 7: 145–173
   Google Scholar
• Thomas M. J., Kemeny D. M. Novel CD4 and CD8 T cell subsets. Allergy 1998; 53: 1122–1132
   PubMed Web of Science ®Google Scholar
• Daugelat S., Kauffman S. H.E. Role of Th1 and Th2 cells in bacterial infections. Chem. Immunol. 1996; 63: 66–69
   PubMedGoogle Scholar
• Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997; 18: 263–266
   PubMedGoogle Scholar
• Wegman T. G., Lin H., Guilbert L., Mosmann T. R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon. Immunol. Today 1993; 14: 353–356
   PubMedGoogle Scholar
• Piccinni M.-P., Giudizi M.-G., Biagiotti R., Beloni L., Giannarini L., Sampognaro S., Parronchi P., Manetti R., Annunziato F., Livi C., Romagnani S., Maggi E. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol. 1995; 155: 128–133
   PubMed Web of Science ®Google Scholar
• Romagnani S. The Th1/Th2 Paradigm in Disease, R.G. Landes company. Springer-Verlag, Austin 1997
   Google Scholar
• Viola J. P.B., Rao A. Molecular regulation of cytokine gene expression during the immune response. J. Clin. Immunol. 1999; 19: 98–108
   Google Scholar
• Murphy M. K., Ouyang W., Farrar J. D., Yang J., Ranganath S., Asnagli H., Afkarian M., Murphy T. L. Signaling and transcription in T helper development. Annu. Rev. Immunol. 2000; 18: 451–494
   PubMed Web of Science ®Google Scholar
• Kaplan M. H., Sun Y. L., Hoey T., Grusby M. J. Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature 1996; 382: 174–177
   PubMed Web of Science ®Google Scholar
• Kaplan M. H., Schindler U., Smiley S. T., Grusby M. J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313–319
   PubMed Web of Science ®Google Scholar
• Haspel R. L., Salditt-Georgief M., Darnell J. E., Jr. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EM BO J. 1996; 15: 6262–6268
   PubMed Web of Science ®Google Scholar
• Starr R., Willson T. A., Viney E. M., Murray L. J.L., Rayner J. R., Jenkins B. J., Gonda T. J., Alexander W. S., Metcalf D., Nicola N. A., Hilton D. J. A family of cytokine-inducible inhibitors of signaling. Nature 1997; 387: 917–921
   PubMed Web of Science ®Google Scholar
• Altare F., Durandy A., Lammas D., Emile J.-F., Lamhamedi S., Diest F., Drysdale P., Jouanguy E., Doffinger R., Bernaudin F., Jeppsson O., Gollob J. A., Meinl E., Segal A. W., Fisher A., Kumararatne D., Casanova J.-L. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280: 1432–1435
   PubMed Web of Science ®Google Scholar
• Schwartz R. Models of T cell anergy: Is there a common molecular mechanism. J. Exp. Med. 1996; 184: 1–6
   PubMed Web of Science ®Google Scholar
• Garcia S., DiSanto J., Stockinger B. Following the development of a CD4 T cell response in vivo: from activation to memory formation. Immunity 1999; 11: 163–171
   PubMed Web of Science ®Google Scholar
• Tsuruta L., Arai N., Arai K.-I. Transcriptional control of cytokine genes. Intern. Rev. Immunol. 1998; 16: 581–616
   PubMedGoogle Scholar
• Neumann M., Grieshammer T., Chuvpilo S., Kneitz B., Lohoff M., Schimpl A., Franza B. R., Jr., Serfling E. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EM BO J. 1995; 14: 1991–2004
   PubMed Web of Science ®Google Scholar
• Kuo C. T., Leiden J. M. Transcriptional regulation of T lymphocyte development and function. Annu. Rev. Immunol. 1999; 17: 149–187
   PubMed Web of Science ®Google Scholar
• Degermann S., Reilly C., Scott B., Ogata L., von Boehmer H., Lo D. On the various manifestations of spontaneous diabetes in rodent models. Eur. J. Immunol. 1994; 24: 3155–3160
   PubMed Web of Science ®Google Scholar
• Pauza M. E., Nguyen A., Wolfe T., Ho I. C., Glimcher L. H., von Herrath M., Lo D. D. Variable effects of transgenic c-Maf on autoimmune diabetes. Diabetes 2001; 50: 39–46
   PubMed Web of Science ®Google Scholar
• Debray-Sachs M., Carnaud C., Boitard C., Cohen H., Gresser I., Bedossa P., Bach J.-F. Prevention of diabetes in NOD mice treated with antibody to murine IFN-gamma. J. Autoimmun. 1991; 4: 237–248
   PubMed Web of Science ®Google Scholar
• Clark B. R., Desphande S. V., Sharma S. D., Nag B. Antigen-specific deletion of cloned T cells using peptide-toxin conjugate complexed with purified class II major histocompatibility complex antigen. J. Biol. Chem. 1994; 269: 94–99
   PubMed Web of Science ®Google Scholar
• Ishioka G. Y., Lamont A. G., Bulbow N., Gaeta F. C., Settte A., Gray M. H. MHC interaction and T cell recognition of carbohydrates and glycopeptides. J. Immunol. 1992; 148: 2446–2451
   PubMed Web of Science ®Google Scholar
• Brumeanu T.-D., Dehazya P., Wolf I., Bona C. A. Enzymatically mediated, glycosidic conjugation of immunoglobulins with viral epitopes. J. Immunol. Methods 1995; 183: 185–197
   PubMed Web of Science ®Google Scholar
• Blum R. H., Carter S. K. Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med. 1974; 80: 249–259
   PubMed Web of Science ®Google Scholar
• Tewey K. M., Rowe T. C., Yang L., Halligan B. D., Liu L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–468
   PubMed Web of Science ®Google Scholar
• Wang H., et al. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase II α in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem. Biophys. Res. Commun. 1997; 237: 217–224
   PubMed Web of Science ®Google Scholar
• Tritton T. R. Cell surface actions of adriamycin. Pharmacol Ther. 1991; 49: 293–309
   PubMed Web of Science ®Google Scholar